Technical Analysis for ZLAB - Zai Lab Limited
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 26.43 | 2.84% | 0.73 |
ZLAB closed up 2.84 percent on Friday, November 22, 2024, on 63 percent of normal volume. It ran into resistance at its 50 day moving average. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 50 DMA Resistance | Bearish | 2.84% | |
| Wide Bands | Range Expansion | 2.84% | |
| Oversold Stochastic | Weakness | 2.84% | |
| 50 DMA Resistance | Bearish | 0.76% | |
| MACD Bearish Centerline Cross | Bearish | 0.76% |
| Alert | Time |
|---|---|
| 50 DMA Resistance | about 11 hours ago |
| 60 Minute Opening Range Breakout | about 14 hours ago |
| Rose Above Previous Day's High | about 14 hours ago |
| Rose Above 50 DMA | about 14 hours ago |
| Outside Day | about 14 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Natural Sciences Infectious Diseases Medication Chemical Substances Autoimmune And Infectious Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Natural Sciences Infectious Diseases Medication Chemical Substances Autoimmune And Infectious Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 36.6 |
| 52 Week Low | 13.48 |
| Average Volume | 961,065 |
| 200-Day Moving Average | 20.28 |
| 50-Day Moving Average | 26.60 |
| 20-Day Moving Average | 29.12 |
| 10-Day Moving Average | 27.34 |
| Average True Range | 1.73 |
| RSI (14) | 44.13 |
| ADX | 30.28 |
| +DI | 21.96 |
| -DI | 32.10 |
| Chandelier Exit (Long, 3 ATRs) | 31.42 |
| Chandelier Exit (Short, 3 ATRs) | 30.06 |
| Upper Bollinger Bands | 33.65 |
| Lower Bollinger Band | 24.60 |
| Percent B (%b) | 0.2 |
| BandWidth | 31.08 |
| MACD Line | -0.36 |
| MACD Signal Line | 0.34 |
| MACD Histogram | -0.6956 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 28.68 | ||||
| Resistance 3 (R3) | 28.51 | 27.58 | 28.31 | ||
| Resistance 2 (R2) | 27.58 | 27.01 | 27.67 | 28.18 | |
| Resistance 1 (R1) | 27.01 | 26.66 | 27.30 | 27.18 | 28.05 |
| Pivot Point | 26.08 | 26.08 | 26.23 | 26.17 | 26.08 |
| Support 1 (S1) | 25.51 | 25.51 | 25.80 | 25.68 | 24.81 |
| Support 2 (S2) | 24.58 | 25.16 | 24.67 | 24.68 | |
| Support 3 (S3) | 24.01 | 24.58 | 24.56 | ||
| Support 4 (S4) | 24.18 |
